Halo Biosciences
CompanyUnited States
Halo Biosciences develops 2 assets, the furthest in phase 2 (H01 in interstitial lung disease). Mostly small molecule; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
2Inhibits hyaluronan synthesis to reduce inflammatory, fibrotic, and metabolic signaling.
Phase 2, Small molecule, interstitial lung disease, pulmonary hypertension
Inhibits hyaluronan synthesis to reduce inflammatory, fibrotic, and metabolic signaling.
Stage not known, Small molecule
Full company profiles: pipeline, trials, funding and people.
In the full profile
- People17
- Similar companies6